|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori infection in subjects negative for high titer serum antibody显示文摘AIM To investigate the clinicopathological features of the patients testing negative for high titer serum antiHelicobacter pylori(H. pylori) antibody.METHODS The antibody titers were measured using antigens derived from Japanese individuals. ^(13)C-urea breath test-positive individuals were defined as having H. pylori infection. We investigated the demographic characteristics, laboratory data, endoscopic findings including Kyoto classification of gastritis, and histology in negative-high titer patients without H. pylori eradication therapy. Kyoto classification consisted of scores for gastric atrophy, intestinal metaplasia, enlarged folds, nodularity, and redness.RESULTS Of the 136 subjects enrolled, 23(17%) had H. pylori infection. Kyoto classification had an excellent area under the receiver operating characteristics curve(0.886, 95% confidence interval: 0.803-0.968, P = 3.7 × 10^(-20)) for predicting H. pylori infection with a cutoff value of 2. Further, Kyoto classification, H. pylori density, and neutrophil activity had high accuracies(89.7%, 96.3%, and 94.1%, respectively). Kyoto classification was independent of the demographic and laboratory parameters in multivariate analysis.CONCLUSION Endoscopic Kyoto classification of gastritis is a useful predictor of H. pylori infection in negative-high titer antibody patients. | Osamu Toyoshima Toshihiro Nishizawa Masahide Arita Yosuke Kataoka Kosuke Sakitani Shuntaro Yoshida Hiroharu Yamashita Keisuke Hata Hidenobu Watanabe Hidekazu Suzuki | 2018 | World Journal of Gastroenterology2018，24，13： | 9 |
| 2 | Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity,atrophy,and age:A cross-sectional study显示文摘AIM To clarify the role of serum anti-Helicobacter pylori(H. pylori) antibody titers in gastric cancer.METHODS In this cross-sectional study, the effect of patients' baseline characteristics and endoscopic findings on their serum antibody titers were assessed. We evaluated consecutive patients who underwent esophagogastroduodenoscopy and their first evaluation for H. pylori infection using a serum antibody test. We excluded patients with a history of eradication therapy. The participants were divided into four groups according to their E-plate serum antibody titer. Patients with serum antibody titers < 3, 3-9.9, 10-49.9, and ≥ 50 U/m L were classified into groups A, B, C, and D, respectively. RESULTS In total, 874 participants were analyzed with 70%, 16%, 8.7%, and 5.1% of them in the groups A, B, C, and D, respectively. Patients in group C were older than patients in groups A and B. Gastric open-type atrophy, intestinal metaplasia, enlarged folds, diffuse redness, and duodenal ulcers were associated with a high titer. Regular arrangements of collecting venules, fundic gland polyps, superficial gastritis, and gastroesophageal reflux disease were related to a low titer. Multivariate analysis revealed that nodularity(P = 0.0094), atrophy(P = 0.0076), and age 40-59 years(vs age ≥ 60 years, P = 0.0090) were correlated with a high serum antibody titer in H. pylori-infected patients. Intestinal metaplasia and atrophy were related to age ≥ 60 years in group C and D.CONCLUSION Serum antibody titer changes with age, reflects gastric mucosal inflammation, and is useful in predicting the risk of gastric cancer. | Osamu Toyoshima Toshihiro Nishizawa Kosuke Sakitani Tadahiro Yamakawa Yoshiyuki Takahashi Nobutake Yamamichi Keisuke Hata Yasuyuki Seto Kazuhiko Koike Hidenobu Watanabe Hidekazu Suzuki | 2018 | World Journal of Gastroenterology2018，24，35： | 9 |
| 3 | Nomograms for colorectal cancer:A systematic review显示文摘AIM: To assist in the selection of suitable nomograms for obtaining desired predictions in daily clinicalpractice.METHODS: We conducted electronic searches for journal articles on colorectal cancer(CRC)-associated nomograms using the search terms colon/rectal/colorectal/nomogram. Of 174 articles initially found, we retrieved 28 studies in which a nomogram for CRC was developed.RESULTS: We discuss the currently available CRCassociated nomograms, including those that predict the oncological prognosis, the short-term outcome of treatments, such as surgery or neoadjuvant chemoradiotherapy, and the future development of CRC. Developing nomograms always presents a dilemma. On the one hand, the desire to cover as wide a patient range as possible tends to produce nomograms that are too complex and yet have C-indexes that are not sufficiently high. Conversely, confining the target patients might impair the clinical applicability of constructed nomograms.CONCLUSION: The information provided in this review should be of use in selecting a nomogram suitable for obtaining desired predictions in daily clinical practice. | Kazushige Kawai Eiji Sunami Hironori Yamaguchi Soichiro Ishihara Shinsuke Kazama Hiroaki Nozawa Keisuke Hata Tomomichi Kiyomatsu Junichiro Tanaka Toshiaki Tanaka Takeshi Nishikawa Joji Kitayama Toshiaki Watanabe | 2015 | World Journal of Gastroenterology2015，21，41： | 5 |
| 4 | Breakthrough therapy for peritoneal carcinomatosis of gastric cancer:Intraperitoneal chemotherapy with taxanes显示文摘The effect of chemotherapy on peritoneal carcinomatosis(PC) of gastric cancer remains unclear.Recently,the intraperitoneal(IP) administration of taxanes [e.g.,paclitaxel(PTX) and docetaxel(DOC)] during the perioperative period has shown promising results.Herein,we summarized the rationale and methodology for using IP chemotherapy with taxanes and reviewed the clinical results.IP administered taxanes remain in the IP space at an extremely high concentration for 48-72 h.The drug directly infiltrates peritoneal metastatic nodules from the surface and then produces antitumor effects,making it ideal for IP chemotherapy.There are two types of perioperative IP chemotherapy with taxanes: neoadjuvant intraperitoneal and systemic chemotherapy and sequential perioperative intraperitoneal chemotherapy(SPIC).In SPIC,patients receive neoadjuvant IP chemotherapy and the same regimen of IP chemotherapy after cytoreductive surgery(CRS) until disease progression.Usually,a taxane dissolved in 500-1000 m L of saline at ordinary temperature is administered through an IP access port on an outpatient basis.According to phase Ⅰ?studies,the recommended doses(RD) are as follows: IP DOC,45-60 mg/m2; IP PTX [without intravenous(IV) PTX],80 mg/m2; and IP PTX(with IV PTX),20 mg/m2.Phase Ⅱ studies have reported a median survival time of 14.4-24.6 mo with a 1-year overall survival of 67%-78%.A phase Ⅲ study comparing S-1 in combination with IP and IV PTX to S-1 with IV cisplatin started in 2011.The prognosis of patients who underwent CRS was better than that of those who did not; however,this was partly due to selection bias.Although several phase Ⅱ studies have shown promising results,a randomized controlled study is needed to validate the effectiveness of IP chemotherapy with taxanes for PC of gastric cancer. | Hironori Yamaguchi Joji Kitayama Hironori Ishigami Shinsuke Kazama Hiroaki Nozawa Kazushige Kawai Keisuke Hata Tomomichi Kiyomatsu Toshiaki Tanaka Junichiro Tanaka Takeshi Nishikawa Kensuke Otani Koji Yasuda Soichiro Ishihara Eiji Sunami Toshiaki Watanabe | 2015 | World Journal of Gastrointestinal Oncology2015，7，11： | 3 |
| 5 | Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection显示文摘 | Akito Hata Nobuyuki Katakami Hiroshige Yoshioka Shiro Fujita Kei Kunimasa Shigeki Nanjo Kyoko Otsuka Reiko Kaji Keisuke Tomii Masahiro Iwasaku Akihiro Nishiyama Hidetoshi Hayashi Satoshi Morita Tadashi Ishida | 2011 | Lung Cancer2011，，2： | 1 |
| 6 | Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures显示文摘 | Keisuke Hata Nobutaka Tanaka Yukihiro Nomura Ikuo Wada Hirokazu Nagawa | 2002 | Journal of Gastroenterology2002，，3： | 1 |
| 7 | Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: A potential of hormone-guided treatment显示文摘 | Keisuke Kawai Katsuya Hata Hideyuki Takaoka Hiroya Kawai Mitsuhiro Yokoyama | 2001 | American Heart Journal2001，，6： | 1 |
| 8 | Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures显示文摘 | Keisuke Hata Nobutaka Tanaka Yukihiro Nomura Ikuo Wada Hirokazu Nagawa | 2002 | Journal of Gastroenterology2002，，3： | 1 |
| 9 | Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures显示文摘 | Keisuke Hata Nobutaka Tanaka Yukihiro Nomura Ikuo Wada Hirokazu Nagawa | 2002 | Journal of Gastroenterology2002，，3： | 1 |
| 10 | Cytomegalovirus infection in ulcerative colitis显示文摘 | Tetsu Kojima Toshiaki Watanabe Keisuke Hata Masaru Shinozaki Tadashi Yokoyama Hirokazu Nagawa | 2006 | Scandinavian Journal of Gastroenterology2006，，： | 1 |
| 11 | Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: A potential of hormone-guided treatment显示文摘 | Keisuke Kawai Katsuya Hata Hideyuki Takaoka Hiroya Kawai Mitsuhiro Yokoyama | 2001 | American Heart Journal2001，，6： | 1 |
| 12 | CASE REPORT: K- ras Mutation and Loss of Heterozygosity at 17p with β-Catenin Accumulation in Intramucosal Carcinoma of the Ileostomy in Familial Adenomatous Polyposis: A Case Report显示文摘 | Keisuke Hata Toshiaki Watanabe Yutaka J. Kawamura Hironori Ishigami Takamitsu Kanazawa Tomohiro Tada Bin Zhao Shinichiro Koketsu Hirokazu Nagawa | 2003 | Digestive Diseases and Sciences2003，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员